- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05630183
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
April 23, 2024 updated by: Agenus Inc.
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective, multicenter, clinical trial of botensilimab in combination with nab-paclitaxel + gemcitabine or nab-paclitaxel + gemcitabine alone.
The trial will be conducted in 2 parts.
Part 1 will be a safety lead-in to establish the safety and dose of botensilimab for Part 2. Part 2 will be a randomized, open-label assessment of botensilimab (at the dose level determined in Part 1).
Study Type
Interventional
Enrollment (Estimated)
78
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Agenus, Inc. Clinical Trial Information
- Phone Number: 781-674-4265
- Email: clinicaltrialinfo@Agenusbio.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- HonorHealth
-
Principal Investigator:
- Erkut Borazanci
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- USC Norris Comprehensive Cancer Center
-
Principal Investigator:
- Diana Hanna
-
Newport Beach, California, United States, 92663
- Recruiting
- USC Norris Oncology
-
Principal Investigator:
- Diana Hanna
-
Santa Monica, California, United States, 90404
- Recruiting
- UCLA Health - Santa Monica Cancer Care
-
Principal Investigator:
- J. Randolph Hecht
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Recruiting
- Medical Oncology Hematology Consultants (MOHC) - Helen F. Graham Cancer Center
-
Principal Investigator:
- Jamal Misleh
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Recruiting
- Florida Cancer Specialist South
-
Principal Investigator:
- Syed Zafar
-
Palm Bay, Florida, United States, 32909
- Recruiting
- Cancer Care Centers of Brevard
-
Principal Investigator:
- Pavan Kancharla
-
Saint Petersburg, Florida, United States, 22705
- Recruiting
- Florida Cancer Specialist North
-
Principal Investigator:
- Maen Hussein
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
- Recruiting
- Illinois Cancer Specialists
-
Principal Investigator:
- Richard Siegel
-
-
Maryland
-
Columbia, Maryland, United States, 21044
- Recruiting
- Maryland Oncology Hematology
-
Principal Investigator:
- Yousuf Gaffar
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Not yet recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Colin Weekes
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Beth Israel Deaconess Medical Center
-
Principal Investigator:
- Andrea Bullock
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- Rogel Cancer Center, University of Michigan Medicine
-
Principal Investigator:
- Thomas Enzler
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Minnesota Oncology
-
Principal Investigator:
- Timothy Larson
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- Not yet recruiting
- Nebraska Medicine-Nebraska Medical Center
-
Principal Investigator:
- Kelsey Klute
-
-
Nevada
-
Las Vegas, Nevada, United States, 89144
- Not yet recruiting
- Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II*
-
Principal Investigator:
- Brian Vicuna
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center at Hackensack
-
Principal Investigator:
- Martin Gutierrez
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Atlantic Health Systems, Morristown
-
Principal Investigator:
- Angela Alistar
-
Summit, New Jersey, United States, 07901
- Recruiting
- Overlook Medical Center
-
-
New York
-
New York, New York, United States, 10065
- Not yet recruiting
- Memorial Sloan Kettering Cancer Center
-
Principal Investigator:
- Eileen O'Reilly
-
New York, New York, United States, 10021
- Recruiting
- Weill Cornell Medicine-New York Presbyterian Hospital
-
Principal Investigator:
- Pashtoon Kasi
-
New York, New York, United States, 10065
- Recruiting
- Weill Cornell Medicine Sandra and Edward Meyer Cancer Center
-
Principal Investigator:
- Pashtoon Kasi
-
New York, New York, United States, 10128
- Recruiting
- Icahn School of Medicine at Mount Sinai Tisch Cancer Institute
-
Principal Investigator:
- Deirdre Cohen
-
-
Ohio
-
Cincinnati, Ohio, United States, 45245
- Recruiting
- Oncology Hematology Care - Eastgate
-
Principal Investigator:
- Mark Johns
-
Cincinnati, Ohio, United States, 45245
- Recruiting
- Sarah Cannon Research Institute at Tennessee Oncology
-
Principal Investigator:
- Meredith Pelster
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Lifespan
-
Principal Investigator:
- Alexander Raufi
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute at Tennessee Oncology
-
Principal Investigator:
- Meredith Pelster
-
-
Texas
-
Carrollton, Texas, United States, 75010
- Recruiting
- Texas Oncology
-
Principal Investigator:
- Enrique Perez
-
Dallas, Texas, United States, 75247
- Recruiting
- Baylor Charles A. Sammons Cancer Center
-
Principal Investigator:
- Scott Paulson
-
Denison, Texas, United States, 75020
- Recruiting
- TxO - Denison Cancer Center
-
Principal Investigator:
- Amir Faridi
-
Fort Worth, Texas, United States, 76104
- Recruiting
- The Center for Cancer & Blood Disorders: Fort Worth
-
Principal Investigator:
- Henry Xiong
-
Tyler, Texas, United States, 75702
- Recruiting
- Northeast Texas Cancer & Research Institute
-
Principal Investigator:
- Donald Richards
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Virginia Cancer Specialists
-
Principal Investigator:
- Alex Spira
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Virginia Oncology Associates - Brock Cancer Center
-
Principal Investigator:
- Yue Zhang
-
Winchester, Virginia, United States, 22601
- Recruiting
- Shenandoah Oncology
-
Principal Investigator:
- William Houck
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute
-
Principal Investigator:
- Philip Gold
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of pancreatic ductal adenocarcinoma.
- Must have had disease progression on any version of FOLFIRINOX for metastatic disease.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Life expectancy of at least 3 months.
- Measurable disease on baseline imaging per RECIST 1.1 criteria.
- < Grade 2 pre-existing peripheral neuropathy per National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0.
- Acceptable coagulation status as indicated by an international normalized ratio ≤ 1.5x institutional ULN, except participants on anticoagulation who can be included at the discretion of the investigator.
- Adequate organ function.
- Women of childbearing potential must have a negative urine or serum pregnancy test at screening (within 72 hours of first dose of study drugs).
- Male participants with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study.
Exclusion Criteria:
- Received more than one prior regimen (that is, FOLFIRINOX) for their metastatic disease.
- History of central nervous system metastasis.
- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study drugs (that is, participants with a history of prior malignancy are eligible if treatment was completed at least 2 years prior to first dose of study drugs and the participant has no evidence of disease). Participants with history of prior early-stage basal/squamous cell skin cancer or noninvasive or in situ cancers who have undergone definitive treatment at any time are also eligible.
- Uncontrolled intercurrent illness, including but not limited to clinically significant (that is, active) cardiovascular disease.
- Active, uncontrolled infections, requiring systemic intravenous anti-infective treatment within 2 weeks prior to first dose of study drugs.
- Major surgery within 4 weeks prior to signing of informed consent form (ICF).
- Prior treatment with an immune checkpoint inhibitor.
- Refractory ascites.
- Partial or complete bowel obstruction within the last 3 months prior to signing ICF, signs/symptoms of bowel obstruction, or known radiologic evidence of impending obstruction.
- Clinically significant gastrointestinal disorders.
Treatment with one of the following classes of drugs within the delineated time window prior to first dose of study drugs:
- Cytotoxic agent within 3 weeks.
- Monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or investigational drug, within 4 weeks, or 5 half-lives, whichever is shorter.
- Small molecule/tyrosine kinase inhibitors within 14 days.
- Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to first dose of study drugs.
- SARS-CoV-2 vaccine < 7 days prior to first dose of study drugs.
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- Symptomatic interstitial lung disease (ILD), history of ILD or any lung disease which may interfere with detection and management of new immune-related pulmonary toxicity.
- History of allogeneic organ transplant.
- Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Participants with a condition requiring systemic treatment with either corticosteroids (> 10 milligrams [mg] daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days prior to first dose of study drugs. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent), are permitted in the absence of active autoimmune disease.
- Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years prior to first dose of study drugs (that is, with use of disease-modifying agents or immunosuppressive drugs).
- Pregnant or breastfeeding participants.
- Uncontrolled infection with human immunodeficiency virus.
- Known to be positive for hepatitis B (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection.
- Known active hepatitis C as determined by positive serology and confirmed by polymerase chain reaction.
- Dependence on total parenteral nutrition.
- Participants with concurrent diarrhea > grade 1 at time of randomization despite optimal treatment with standard of care pancreatic enzymes.
- Known active or latent tuberculosis (testing at screening not required).
- Any condition in the opinion of the principal investigator that might interfere with the participant's participation in the study or in the evaluation of the study results.
- Unwillingness or inability to comply with procedures required in this protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Combination (Safety Lead-in Phase)
Participants will receive botensilimab in combination with standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
|
A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Other Names:
Standard-of-care chemotherapy administered intravenously.
Standard-of-care chemotherapy administered intravenously.
|
Experimental: Part 2: Combination
Participants will receive botensilimab in combination standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
|
A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Other Names:
Standard-of-care chemotherapy administered intravenously.
Standard-of-care chemotherapy administered intravenously.
|
Active Comparator: Part 2: Standard of Care
Participants will receive standard-of-care chemotherapy (nab-paclitaxel + gemcitabine).
|
Standard-of-care chemotherapy administered intravenously.
Standard-of-care chemotherapy administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: Up to 2 years
|
Progression-free survival will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression, assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), or death, whichever occurs first.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number Of Participants With Treatment-emergent Adverse Events
Time Frame: First study dose through up 1 year
|
First study dose through up 1 year
|
|
Overall Survival
Time Frame: Up to 2 years
|
Overall survival will be defined as the time from the date of randomization to the date of death due to any cause.
|
Up to 2 years
|
Complete Response
Time Frame: Up to 2 years
|
Complete response will be defined by RECIST 1.1 criteria and carbohydrate antigen 19-9 down to normal limits (from at least > 2x upper limit of normal [ULN]).
Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
|
Up to 2 years
|
Overall Response Rate
Time Frame: Up to 2 years
|
Overall response rate will be defined as the proportion of participants whose best overall response is complete response or partial response per RECIST v1.1.
|
Up to 2 years
|
Duration Of Response
Time Frame: Up to 2 years
|
Duration of response will be defined as the time from the first determination of an objective response per RECIST v1.1, until the first documentation of progression or death, whichever occurs first.
|
Up to 2 years
|
Change From Baseline In Carbohydrate Antigen 19-9
Time Frame: Baseline, 2 years
|
Change in carbohydrate antigen 19-9 will be evaluated until progressive disease, death, date of last tumor assessment, or start of new anti-cancer therapy.
Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
|
Baseline, 2 years
|
Rates Of Normalization Of Carbohydrate Antigen 19-9
Time Frame: Up to 2 years
|
Carbohydrate antigen 19-9 normalization will be defined as a value of carbohydrate antigen 19-9 down to normal limits (from at least > 2x ULN).
Cancer antigen 125 or carcinoembryonic antigen will be evaluated for participants who are not expressors of carbohydrate antigen 19-9.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Agenus Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 18, 2022
First Submitted That Met QC Criteria
November 18, 2022
First Posted (Actual)
November 29, 2022
Study Record Updates
Last Update Posted (Estimated)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-800-22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Ductal Adenocarcinoma
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
Sierra Oncology LLC - a GSK companyTerminatedMetastatic Pancreatic Ductal AdenocarcinomaUnited States
-
PfizerCelgeneCompletedMetastatic Pancreatic Ductal AdenocarcinomaUnited States, Spain
-
Belgian Group of Digestive OncologyUniversity Hospital St Luc, BrusselsRecruitingMetastatic Pancreatic Ductal AdenocarcinomaBelgium
-
British Columbia Cancer AgencyCanadian Cancer Society (CCS); SignalChem Lifesciences CorporationRecruitingMetastatic Pancreatic Ductal AdenocarcinomaCanada
-
University Hospital, AntwerpUniversitair Ziekenhuis Brussel; General Hospital Groeninge; AZ Nikolaas; Erasme... and other collaboratorsActive, not recruitingMetastatic Pancreatic Ductal AdenocarcinomaBelgium
Clinical Trials on Botensilimab
-
Agenus Inc.SuspendedAdvanced MelanomaUnited States, Spain, United Kingdom, France, Germany, Switzerland, Belgium, Italy, Brazil, Russian Federation
-
Weill Medical College of Cornell UniversityAgenus Inc.Recruiting
-
Immune Oncology Research InstituteAgenus Inc.Not yet recruiting
-
Agenus Inc.Active, not recruitingAdvanced CancerUnited States
-
The Netherlands Cancer InstituteAgenus Inc.RecruitingResectable MMR-deficient Solid Tumors | Resectable MMR-proficient Solid TumorsNetherlands
-
Agenus Inc.Active, not recruiting
-
Agenus Inc.RecruitingMelanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver MetastasesUnited States
-
Weill Medical College of Cornell UniversityAgenus Inc.RecruitingColorectal Cancer | Colorectal Cancer Metastatic | Liver MetastasesUnited States
-
Agenus Inc.Active, not recruitingMetastatic Colorectal CancerUnited States, France, Spain, Belgium, Italy, Brazil, Russian Federation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Agenus Inc.; Dutch Cancer SocietyNot yet recruiting